Multicenter, Non-Comparative, Open-Label Study to Evaluate the Safety and Efficacy of Enoxaparin Sodium (RP54563) 20 mg Bid for 14 Days in Patients With Hip Fracture Surgery
Phase of Trial: Phase III
Latest Information Update: 19 Nov 2013
At a glance
- Drugs Enoxaparin sodium (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
- Sponsors Sanofi
- 07 Oct 2009 Last checked against ClinicalTrials.gov record.
- 14 Jun 2008 New trial record.